Literature DB >> 20868309

Hyperuricaemia and accelerated reduction in renal function.

C-F Kuo1, S-F Luo, L-C See, Y-S Ko, Y-M Chen, J-S Hwang, I-J Chou, H-C Chang, H-W Chen, K-H Yu.   

Abstract

OBJECTIVES: Hyperuricaemia has been linked to reduced renal function, and evidence indicates that it may be associated with acceleration of the decline in glomerular filtration rate (GFR) and progression of chronic kidney disease (CKD).
METHODS: We analysed a population of subjects who had undergone serum uric acid (SUA) and serum creatinine measurements in a hospital-based cohort. Initial and final serum creatinine measurements were used to calculate the estimated glomerular filtration rate (eGFR) and the annual decline in eGFR. Cox regression was used to investigate the relationship between SUA and CKD progression.
RESULTS: A total of 63,785 subjects were enrolled in the study during a 12-year follow-up period. The mean age at the time of initial serum creatinine measurement was 50.0 ± 14.9 years. Hyperuricaemic subjects had a significantly larger annual eGFR decline, both in absolute terms (2.5 ± 9.5 mL/min/1.73 m(2) per year) and as a percentage (2.8 ± 11.6% per year), as compared to the normouricaemia group (1.3 ± 9.6 mL/min/1.73 m(2) per year, 1.1 ± 11.1% per year, p < 0.001). After adjustment for age, sex, status of diabetes mellitus (DM) and hypertension, baseline eGFR, azotaemia, hypercholesterolaemia, and hyperglycaemia, hyperuricaemia was associated with a hazard ratio (HR) of 1.28 [95% confidence interval (CI) 1.23-1.33, p < 0.001] for an accelerated eGFR decline ≥ 3 mL/min/1.73 m(2) per year and an HR of 1.52 (95% CI 1.46-1.59) for CKD progression at the end of follow-up.
CONCLUSION: Hyperuricaemia was associated with an accelerated decline in eGFR and higher risk of CKD progression. Therefore, renal function should be monitored closely in patients with hyperuricaemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868309     DOI: 10.3109/03009742.2010.507218

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  22 in total

Review 1.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

2.  Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.

Authors:  Hakan Nacak; Merel van Diepen; Abdul R Qureshi; Juan J Carrero; Theo Stijnen; Friedo W Dekker; Marie Evans
Journal:  Nephrol Dial Transplant       Date:  2015-07-16       Impact factor: 5.992

Review 3.  Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors".

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  World J Nephrol       Date:  2014-08-06

4.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.

Authors:  Mehmet Kanbay; Bulent Huddam; Alper Azak; Yalcin Solak; Gulay Kocak Kadioglu; Ismail Kirbas; Murat Duranay; Adrian Covic; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

Review 5.  The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review.

Authors:  G Zoppini; G Targher; E Bonora
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

Review 6.  Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.

Authors:  David M Maahs; Luiza Caramori; David Z I Cherney; Andrzej T Galecki; Chuanyun Gao; Diana Jalal; Bruce A Perkins; Rodica Pop-Busui; Peter Rossing; Michael Mauer; Alessandro Doria
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 7.  Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.

Authors:  Tahir Kanji; Mandark Gandhi; Catherine M Clase; Robert Yang
Journal:  BMC Nephrol       Date:  2015-04-19       Impact factor: 2.388

8.  Association of serum uric acid with proteinuria in type 2 diabetic patients.

Authors:  Saeed Behradmanesh; Mohammad Karami Horestani; Azar Baradaran; Hamid Nasri
Journal:  J Res Med Sci       Date:  2013-01       Impact factor: 1.852

9.  Commentary on: The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia.

Authors:  Hamid Nasri
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

10.  Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents.

Authors:  Macaulay Onuigbo
Journal:  Nephron Extra       Date:  2013-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.